



EPIGENE LABS ANNOUNCES MULTI-YEAR EXPANSION OF COLLABORATION WITH SERVIER TO ADVANCE AI-DRIVEN PRECISION ONCOLOGY R&D

- **Collaboration combines Epigene's mCUBE platform for seamless integration of multi-omic data from diverse sources and proprietary analytical toolbox with Servier's precision oncology expertise**
- **Collaboration aims to accelerate and increase precision of Servier's oncology clinical trials via patient selection, disease modeling and biomarker identification enabled by Epigene's mCUBE platform**

PARIS, France, and CAMBRIDGE, Massachusetts, March 6th, 2025 – Epigene Labs, a techbio company focused on creating intelligence-augmenting solutions for precision oncology, today announced an expanded multi-year collaboration with Servier, an independent international pharmaceutical group. Building on a successful partnership initiated in oncology research, this ambitious expansion aims to provide access for Servier to a harmonized clinical and multi-omic data to fuel the pharmaceutical company's disease modeling, biomarker identification, and patient selection strategies.

Epigene Labs will deploy its proprietary mCUBE platform, a suite of intelligence-augmenting solutions designed to transform fragmented multi-omic datasets into structured, ready-to-use data for oncology R&D. The initiative aims to accelerate oncology drug discovery and development by achieving interoperability of complex molecular and clinical data. Financial terms of the collaboration were not disclosed.

"This partnership marks a significant step towards realizing our vision of augmented intelligence in cancer research and drug development," said Akpéli Nordor, Co-founder & CEO of Epigene Labs. "By leveraging our mCUBE platform to integrate multi-omic datasets at an unprecedented scale, we are supporting Servier's strategic efforts to harmonize clinical and omic data for a multitude of applications in oncology R&D."

"The future of oncology innovation lies in our ability to develop therapeutics for treating each cancer patient with the right drug by extracting key insights from increasingly complex and voluminous datasets," said Fabien Schmidlin, Global Head of Translational Medicine at Servier. "The expansion of our collaboration with Epigene Labs underscores Servier's commitment to AI-driven, patient-centered innovation in oncology as a highly promising approach for modeling diseases with greater precision, ultimately accelerating the development of transformative treatments for well-defined patient populations."

EPIGENE LABS SAS

Adresse : 7, square Gabriel Fauré 75017 Paris, France
Téléphone : + 33 6 20 07 76 26 – Site web : www.epigenelabs.com
Code NAF/APE : 6201Z – 845 367 713 R.C.S. Paris – Capital de 1 472,20 euros

About Epigene Labs

Epigene Labs creates intelligence-augmenting solutions to accelerate precision oncology research and drug development. By harnessing artificial intelligence and next-generation bioinformatics, its mCUBE platform integrates fragmented multi-omic datasets into comprehensive disease atlases with unprecedented depth and breadth. As a result, mCUBE has significantly impacted various R&D programs on immuno-oncology -- often reducing months of research to mere days. Applications include target discovery, biomarker identification, and patient selection at leading cancer research institutes and biopharmaceutical companies. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and later launched in France with the backing of prominent European investors. The company has also secured backing from the European Commission through the prestigious multi-million-euro EIC Accelerator program.

For more information, visit: www.epigenelabs.com.

Media Contacts:

Lucie Jankovsky
Communication Manager
lucie@epigenelabs.com

EPIGENE LABS SAS

Adresse : 7, square Gabriel Fauré 75017 Paris, France
Téléphone : + 33 6 20 07 76 26 – Site web : www.epigenelabs.com
Code NAF/APE : 6201Z – 845 367 713 R.C.S. Paris – Capital de 1 472,20 euros